On June 6, 2025 Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, reported that the company will host a webcast conference call at 8:00 a.m., ET, on Thursday, June 12, 2025, to discuss new data from the ongoing Phase 1 clinical trial of bexobrutideg (NX-5948) that will be presented at the European Hematology Association (EHA) (Free EHA Whitepaper) Congress in Milan, Italy (Press release, Nurix Therapeutics, JUN 6, 2025, https://ir.nurixtx.com/news-releases/news-release-details/nurix-therapeutics-host-webcast-conference-call-discuss-data [SID1234653761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the webcast and conference call are as follows:

Date and time: Thursday, June 12, 8:00 a.m. ET / 2:00 p.m. CEST

Access details: The live webcast will be accessible on the Events page in the Investors section of the company’s website. To participate in the live conference call, the dial-in number in the U.S. is 877-346-6112. For participants outside the U.S., the dial-in number is 1- 848-280-6350. A replay of the webcast and call will be archived on the Nurix website for approximately 30 days after the event.

Details of the presentations at EHA (Free EHA Whitepaper)2025:

Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study
Presenting author: Talha Munir M.B. Ch.B., Ph.D., Consultant Hematologist at Leeds Teaching Hospitals NHS Trust, Deputy Chair of the United Kingdom National Cancer Research Institute CLL Study Group
Session title: Poster Session 1
Session date and time: Friday, June 13 (18:30 – 19:30 CEST)
Abstract ID: PF571
Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: Dima El-Sharkawi, M.B., B.S., M.A., Ph.D., MRCP FRCPath, Consultant Haematologist, Royal Marsden NHS Foundation Trust, Sutton, UK
Session title: Poster Session 2
Session date and time: Saturday, June 14 (18:30 – 19:30 CEST)
Abstract ID: PS1883
About Bexobrutideg (NX-5948)

Bexobrutideg is an investigational, orally bioavailable, brain penetrant, small molecule degrader of BTK. Bexobrutideg is currently being evaluated in a Phase 1 clinical trial in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trial can be accessed at clinicaltrials.gov (NCT05131022).

On June 6, 2025 Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, reported the grant of inducement equity awards to newly hired non-executive employees (Press release, Replimune, JUN 6, 2025, View Source [SID1234653762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company granted equity awards to 10 employees as a material inducement to commencing their employment with the Company under the Company’s 2025 Inducement Grant Incentive Compensation Plan (the "Inducement Plan"). The inducement awards consist of non-qualified stock options to purchase an aggregate of 36,485 shares of the Company’s common stock and restricted stock units representing an aggregate of 41,080 shares of the Company’s common stock. Each option has an exercise price of $9.75 per share, which is equal to the closing price of the Company’s common stock on June 5, 2025 (the "Date of Grant"). Each option has a 10-year term and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the Date of Grant, and the remainder vesting in monthly installments for three years thereafter. The restricted stock units vest in approximately four equal annual installments beginning on May 15, 2026.

The aforementioned inducement awards were approved by the compensation committee of the Company’s board of directors in reliance on the employment inducement exception under Nasdaq Listing Rule 5635(c)(4). The inducement awards are subject to the terms and conditions set forth under the Inducement Plan.

On June 6, 2025 TG Therapeutics, Inc. (NASDAQ: TGTX) reported that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 46th Annual Global Healthcare Conference, being held in Miami, FL on June 9-11, 2025 (Press release, TG Therapeutics, JUN 6, 2025, View Source [SID1234653763]). The fireside chat is scheduled to take place on Tuesday, June 10, 2025, at 10:40am ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at View Source

On June 6, 2025 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported the grants of inducement restricted stock units ("RSUs") to 27 new employees in connection with their employment with UroGen (Press release, UroGen Pharma, JUN 6, 2025, View Source [SID1234653764]). These new team members will support the ongoing commercialization of Jelmyto (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the continued development of the Company’s pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Up to 118,000 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.

The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).

On June 6, 2025 Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL gene silencing technology to treat cancer, reported a strategic initiative to heighten awareness of potential applications of the broader INTASYL siRNA portfolio, which includes approximately 30 compounds (Press release, Phio Pharmaceuticals, JUN 6, 2025, View Source [SID1234653765]). Recently, positive interim safety and efficacy results were reported in the on-going Phase 1b dose escalation clinical trial with the INTASYL compound PH-762 for the treatment of skin cancer. Clinical and preclinical data to date suggest promise for other potential applications across the INTASYL portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Robert Infarinato has been appointed to the role of VP, Strategic Development, effective June 9, 2025. He will be transitioning from his role as Chief Financial Officer to concentrate on directing strategic business development initiatives focusing on potential applications of the broader INTASYL portfolio. Concurrently, Ms. Lisa Carson, was appointed VP, Finance and Administration and will lead Phio’s finance team.

Mr. Infarinato has over 30 years of finance and accounting leadership experience. He served as head of a consulting firm, advising on operational matters including funding and IPO process. Previous positions include serving as Chairman of the Board of Trustees for Abington Health and as executive Vice President and CFO of an international service company.

Ms. Carson joined Phio in May 2025 with more than 20 years of finance and accounting leadership experience. She most recently was VP, Finance and Controller at Prelude Therapeutics, where she supported the company’s IPO and expansion. Ms. Carson also held leadership roles at TELA Bio and PhaseBio Pharmaceuticals.

"It is a great pleasure to announce the new positions of these two experienced professionals," said Robert Bitterman, Phio’s CEO and President. "This strategic move underscores the company’s commitment to gain greater awareness of the potential applications in our INTASYL siRNA portfolio."